{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:47Z","timestamp":1792017347356,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"crossref","award":["2022-NI-006"],"award-info":[{"award-number":["2022-NI-006"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02680-3","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:42:10Z","timestamp":1741326130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of a novel small-molecule inhibitor of the HIV-1 reverse transcriptase activity with a non-nucleoside mode of action"],"prefix":"10.1186","volume":"22","author":[{"given":"Kyung-Lee","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungHyun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Eun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmee","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2680_CR1","unstructured":"Global HIV & AIDS Statistics https:\/\/www.unaids.org\/en\/resources\/fact-sheet (updated 2 August 2024) [https:\/\/www.unaids.org\/en\/resources\/fact-sheet]"},{"issue":"3","key":"2680_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00002030-200302140-00010","volume":"17","author":"SG Deeks","year":"2003","unstructured":"Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003;17(3):361\u201370.","journal-title":"AIDS"},{"issue":"5341","key":"2680_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295\u2013300.","journal-title":"Science"},{"issue":"5341","key":"2680_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291\u20135.","journal-title":"Science"},{"issue":"24","key":"2680_CR5","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94(24):13193\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2680_CR6","doi-asserted-by":"publisher","first-page":"offa456","DOI":"10.1093\/ofid\/ofaa456","volume":"7","author":"L Galli","year":"2020","unstructured":"Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, et al. Burden of disease in pwh harboring a multidrug-resistant virus: data from the PRESTIGIO registry. Open Forum Infect Dis. 2020;7(11):offa456.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2680_CR7","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1073\/pnas.96.10.5698","volume":"96","author":"M Baba","year":"1999","unstructured":"Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA. 1999;96(10):5698\u2013703.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2680_CR8","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"2680_CR9","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.1128\/JVI.75.18.8605-8614.2001","volume":"75","author":"CA Derdeyn","year":"2001","unstructured":"Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O\u2019Brien WA, Ratner L, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol. 2001;75(18):8605\u201314.","journal-title":"J Virol"},{"issue":"21","key":"2680_CR10","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","volume":"83","author":"PA Furman","year":"1986","unstructured":"Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al. Phosphorylation of 3\u02b9-azido-3\u02b9-deoxythymidine and selective interaction of the 5\u02b9-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 1986;83(21):8333\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4986","key":"2680_CR11","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1126\/science.1701568","volume":"250","author":"VJ Merluzzi","year":"1990","unstructured":"Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990;250(4986):1411\u20133.","journal-title":"Science"},{"issue":"5","key":"2680_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","volume":"43","author":"M Markowitz","year":"2006","unstructured":"Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43(5):509\u201315.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4953","key":"2680_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248(4953):358\u201361.","journal-title":"Science"},{"issue":"4","key":"2680_CR14","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","volume":"12","author":"G Li","year":"2022","unstructured":"Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm Sin B. 2022;12(4):1567\u201390.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"2680_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1086\/381678","volume":"38","author":"PL Anderson","year":"2004","unstructured":"Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38(5):743\u201353.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"5","key":"2680_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb760","volume":"11","author":"S Tuske","year":"2004","unstructured":"Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol. 2004;11(5):469\u201374.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"2680_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nsb0495-293","volume":"2","author":"J Ren","year":"1995","unstructured":"Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol. 1995;2(4):293\u2013302.","journal-title":"Nat Struct Biol"},{"issue":"5065","key":"2680_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1126\/science.1377403","volume":"256","author":"LA Kohlstaedt","year":"1992","unstructured":"Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256(5065):1783\u201390.","journal-title":"Science"},{"issue":"4","key":"2680_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nsb0495-303","volume":"2","author":"R Esnouf","year":"1995","unstructured":"Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol. 1995;2(4):303\u20138.","journal-title":"Nat Struct Biol"},{"issue":"10","key":"2680_CR20","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/v15101992","volume":"15","author":"M Vanangamudi","year":"2023","unstructured":"Vanangamudi M, Palaniappan S, Kathiravan MK, Namasivayam V. Strategies in the design and development of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Viruses. 2023;15(10):1992.","journal-title":"Viruses"},{"key":"2680_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","volume":"54","author":"M Vanangamudi","year":"2020","unstructured":"Vanangamudi M, Kurup S, Namasivayam V. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. Curr Opin Pharmacol. 2020;54:179\u201387.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"2680_CR22","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1128\/AAC.06307-11","volume":"56","author":"P Ordonez","year":"2012","unstructured":"Ordonez P, Hamasaki T, Isono Y, Sakakibara N, Ikejiri M, Maruyama T, Baba M. Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives. Antimicrob Agents Chemother. 2012;56(5):2581\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2680_CR23","first-page":"S45","volume":"10","author":"J Mellors","year":"1995","unstructured":"Mellors J, Larder B, Schinazi R. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. J Acquir Immune Defic Syndr. 1995;10:S45\u2013S45.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"2680_CR24","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/cmdc.201100362","volume":"6","author":"S Alcaro","year":"2011","unstructured":"Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, et al. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. ChemMedChem. 2011;6(12):2203\u201313.","journal-title":"ChemMedChem"},{"issue":"16","key":"2680_CR25","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1128\/JVI.00709-09","volume":"83","author":"EJ Platt","year":"2009","unstructured":"Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol. 2009;83(16):8289\u201392.","journal-title":"J Virol"},{"key":"2680_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jviromet.2016.03.008","volume":"233","author":"L Xing","year":"2016","unstructured":"Xing L, Wang S, Hu Q, Li J, Zeng Y. Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents. J Virol Methods. 2016;233:56\u201361.","journal-title":"J Virol Methods"},{"issue":"6","key":"2680_CR27","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","volume":"46","author":"X Wei","year":"2002","unstructured":"Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46(6):1896\u2013905.","journal-title":"Antimicrob Agents Chemother"},{"key":"2680_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/0471142735.im1203s69","volume":"69","author":"E Vicenzi","year":"2005","unstructured":"Vicenzi E, Poli G. Infection of CD4+ primary T cells and cell lines, generation of chronically infected cell lines, and induction of HIV expression. Curr Protoc Immunol. 2005;69:12.","journal-title":"Curr Protoc Immunol"},{"issue":"8","key":"2680_CR29","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1128\/AAC.00648-12","volume":"56","author":"M Balamane","year":"2012","unstructured":"Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Antimicrob Agents Chemother. 2012;56(8):4522\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2680_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/01.aids.0000166098.54564.0c","volume":"19","author":"E Johnston","year":"2005","unstructured":"Johnston E, Dupnik KM, Gonzales MJ, Winters MA, Rhee SY, Imamichi T, Shafer RW. Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS. 2005;19(7):731\u20133.","journal-title":"AIDS"},{"issue":"19","key":"2680_CR31","doi-asserted-by":"publisher","first-page":"10548","DOI":"10.1128\/JVI.77.19.10548-10556.2003","volume":"77","author":"M Schindler","year":"2003","unstructured":"Schindler M, Wurfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Munch J, Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol. 2003;77(19):10548\u201356.","journal-title":"J Virol"},{"issue":"2","key":"2680_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bbrc.2019.12.029","volume":"523","author":"Y Shin","year":"2020","unstructured":"Shin Y, Kim HG, Park CM, Choi MS, Kim DE, Choi BS, Kim K, Yoon CH. Identification of novel compounds against Tat-mediated human immunodeficiency virus-1 transcription by high-throughput functional screening assay. Biochem Biophys Res Commun. 2020;523(2):368\u201374.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2680_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1128\/jvi.66.4.2232-2239.1992","volume":"66","author":"J Kimpton","year":"1992","unstructured":"Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992;66(4):2232\u20139.","journal-title":"J Virol"},{"issue":"1","key":"2680_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0378-1119(89)90359-4","volume":"77","author":"RM Horton","year":"1989","unstructured":"Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77(1):61\u20138.","journal-title":"Gene"},{"issue":"6","key":"2680_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nprot.2011.330","volume":"6","author":"D Daelemans","year":"2011","unstructured":"Daelemans D, Pauwels R, De Clercq E, Pannecouque C. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc. 2011;6(6):925\u201333.","journal-title":"Nat Protoc"},{"key":"2680_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12977-015-0218-9","volume":"12","author":"MJ Kim","year":"2015","unstructured":"Kim MJ, Kim SH, Park JA, Yu KL, Jang SI, Kim BS, Lee ES, You JC. Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein. Retrovirology. 2015;12:90.","journal-title":"Retrovirology"},{"issue":"22","key":"2680_CR37","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1007\/s00253-017-8544-6","volume":"101","author":"F Marino-Merlo","year":"2017","unstructured":"Marino-Merlo F, Frezza C, Papaianni E, Valletta E, Mastino A, Macchi B. Development and evaluation of a simple and effective RT-qPCR inhibitory assay for detection of the efficacy of compounds towards HIV reverse transcriptase. Appl Microbiol Biotechnol. 2017;101(22):8249\u201358.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"4","key":"2680_CR38","first-page":"e3168","volume":"9","author":"G Laura","year":"2019","unstructured":"Laura G, Moran SP, Ro S, de Noronha CM, Shi B. Analysis of early phase HIV-1 replication and integration events by using real-time PCR. Bio-Protoc. 2019;9(4):e3168\u2013e3168.","journal-title":"Bio-Protoc"},{"issue":"8","key":"2680_CR39","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/acsinfecdis.3c00166","volume":"9","author":"MJ Kim","year":"2023","unstructured":"Kim MJ, Yu KL, Han R, Lee Y, Oh K, You JC. Identification of a non-nucleoside reverse transcriptase inhibitor against human immunodeficiency virus-1. ACS Infect Dis. 2023;9(8):1582\u201392.","journal-title":"ACS Infect Dis"},{"issue":"21","key":"2680_CR40","doi-asserted-by":"publisher","first-page":"12385","DOI":"10.1128\/JVI.00609-14","volume":"88","author":"C Vandergeeten","year":"2014","unstructured":"Vandergeeten C, Fromentin R, Merlini E, Lawani MB, DaFonseca S, Bakeman W, McNulty A, Ramgopal M, Michael N, Kim JH, et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014;88(21):12385\u201396.","journal-title":"J Virol"},{"issue":"1","key":"2680_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-020-01476-x","volume":"18","author":"KH Park","year":"2021","unstructured":"Park KH, Kim M, Bae SE, Lee HJ, Kim KC, Choi BS, Kim YB. Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor. Virol J. 2021;18(1):17.","journal-title":"Virol J"},{"issue":"7","key":"2680_CR42","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1128\/AAC.01828-09","volume":"54","author":"I Lisovsky","year":"2010","unstructured":"Lisovsky I, Schader SM, Martinez-Cajas JL, Oliveira M, Moisi D, Wainberg MA. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother. 2010;54(7):2878\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2680_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1128\/AAC.00689-08","volume":"53","author":"Y Koh","year":"2009","unstructured":"Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 2009;53(3):997\u20131006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2680_CR44","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","volume":"121","author":"ME Cilento","year":"2021","unstructured":"Cilento ME, Kirby KA, Sarafianos SG. Avoiding drug resistance in HIV reverse transcriptase. Chem Rev. 2021;121(6):3271\u201396.","journal-title":"Chem Rev"},{"issue":"2","key":"2680_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"XY Meng","year":"2011","unstructured":"Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146\u201357.","journal-title":"Curr Comput Aided Drug Des"},{"issue":"7","key":"2680_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/ph17070935","volume":"17","author":"P Singh","year":"2024","unstructured":"Singh P, Kumar V, Lee KW, Hong JC. Discovery of novel allosteric SHP2 inhibitor using pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and principal component analysis. Pharmaceuticals. 2024;17(7):935.","journal-title":"Pharmaceuticals"},{"key":"2680_CR47","unstructured":"Dassault systemes BIOVIA, Discovery studio modelling environment, Release 4.5. Accelrys Software Inc. [https:\/\/www.3ds.com\/products\/biovia\/discovery-studio]"},{"issue":"1","key":"2680_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11030-023-10669-9","volume":"28","author":"MB Yadav","year":"2024","unstructured":"Yadav MB, Singh P, Jeong YT. Regioselective synthesis and molecular docking studies of functionalized imidazo [1,2-a]pyridine derivatives through MCRs. Mol Divers. 2024;28(1):171\u201382.","journal-title":"Mol Divers"},{"issue":"24","key":"2680_CR49","doi-asserted-by":"publisher","first-page":"16122","DOI":"10.3390\/ijms232416122","volume":"23","author":"P Singh","year":"2022","unstructured":"Singh P, Kumar V, Lee G, Jung TS, Ha MW, Hong JC, Lee KW. Pharmacophore-oriented identification of potential leads as CCR5 inhibitors to block HIV cellular entry. Int J Mol Sci. 2022;23(24):16122.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2680_CR50","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1046\/j.1432-1327.2002.02811.x","volume":"269","author":"J Lindberg","year":"2002","unstructured":"Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem. 2002;269(6):1670\u20137.","journal-title":"Eur J Biochem"},{"issue":"7","key":"2680_CR51","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/jcc.21726","volume":"32","author":"N Sapay","year":"2011","unstructured":"Sapay N, Tieleman DP. Combination of the CHARMM27 force field with united-atom lipid force fields. J Comput Chem. 2011;32(7):1400\u201310.","journal-title":"J Comput Chem"},{"issue":"1","key":"2680_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425250903490418","volume":"6","author":"PN Kumar","year":"2010","unstructured":"Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6(1):105\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1\u20132","key":"2680_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0166-3542(96)00950-3","volume":"31","author":"K Ijichi","year":"1996","unstructured":"Ijichi K, Fujiwara M, Nagano H, Matsumoto Y, Hanasaki Y, Ide T, Katsuura K, Takayama H, Shirakawa S, Aimi N, et al. Anti-HIV-1 activity of thiadiazole derivatives: structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antivir Res. 1996;31(1\u20132):87\u201394.","journal-title":"Antivir Res"},{"issue":"16","key":"2680_CR54","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1016\/j.bmc.2009.07.004","volume":"17","author":"P Zhan","year":"2009","unstructured":"Zhan P, Liu X, Li Z, Fang Z, Li Z, Wang D, Pannecouque C, Clercq ED. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg Med Chem. 2009;17(16):5920\u20137.","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"2680_CR55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1515\/znb-2015-0032","volume":"70","author":"MUH Khan","year":"2015","unstructured":"Khan MUH, Hameed S, Farman M, Al-Masoudi NA, Stoeckli-Evans H. Synthesis, anti-HIV activity and molecular modeling study of 3-aryl-6-adamantylmethyl-[1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazole derivatives. Zeitschrift f\u00fcr Naturforschung B. 2015;70(8):609\u201316.","journal-title":"Zeitschrift f\u00fcr Naturforschung B"},{"issue":"20","key":"2680_CR56","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1021\/jm800856c","volume":"51","author":"TJ Tucker","year":"2008","unstructured":"Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, et al. Discovery of 3-5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem. 2008;51(20):6503\u201311.","journal-title":"J Med Chem"},{"key":"2680_CR57","doi-asserted-by":"publisher","first-page":"111714","DOI":"10.1016\/j.ejmech.2019.111714","volume":"183","author":"S Kumar","year":"2019","unstructured":"Kumar S, Gupta S, Abadi LF, Gaikwad S, Desai D, Bhutani KK, Kulkarni S, Singh IP. Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives. Eur J Med Chem. 2019;183:111714.","journal-title":"Eur J Med Chem"},{"issue":"19","key":"2680_CR58","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1016\/j.bmcl.2009.08.039","volume":"19","author":"CE Mowbray","year":"2009","unstructured":"Mowbray CE, Burt C, Corbau R, Perros M, Tran I, Stupple PA, Webster R, Wood A. Pyrazole NNRTIs 1: design and initial optimisation of a novel template. Bioorg Med Chem Lett. 2009;19(19):5599\u2013602.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"2680_CR59","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1021\/ml300146q","volume":"3","author":"J Kim","year":"2012","unstructured":"Kim J, Lee D, Park C, So W, Jo M, Ok T, Kwon J, Kong S, Jo S, Kim Y, et al. Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. ACS Med Chem Lett. 2012;3(8):678\u201382.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2680_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkt316","volume":"69","author":"GL Melikian","year":"2014","unstructured":"Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towner W, Troia P, Burack J, Dejesus E, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69(1):12\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2680_CR61","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1128\/AAC.04215-14","volume":"59","author":"AE Basson","year":"2015","unstructured":"Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, et al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015;59(2):960\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2680_CR62","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bmcl.2018.03.012","volume":"28","author":"B Huang","year":"2018","unstructured":"Huang B, Liu X, Tian Y, Kang D, Zhou Z, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X. First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N\/Y181C double mutant strain. Bioorg Med Chem Lett. 2018;28(8):1348\u201351.","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"2680_CR63","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer C, Pozniak A. HIV drug resistance-an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"2680_CR64","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang Y, De Clercq E, Li G. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin Drug Metab Toxicol. 2019;15(10):813\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2680_CR65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jac\/dkaa401","volume":"76","author":"F Saladini","year":"2021","unstructured":"Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccuto A, Dragoni F, Vicenti I, Shafer RW, Zazzi M. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. J Antimicrob Chemother. 2021;76(1):130\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2680_CR66","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/jac\/dkad184","volume":"78","author":"BG Brenner","year":"2023","unstructured":"Brenner BG, Oliveira M, Ibanescu RI, Routy JP, Thomas R. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure. J Antimicrob Chemother. 2023;78(8):1921\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2680_CR67","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","volume":"72","author":"SJ Smith","year":"2016","unstructured":"Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH. Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants. J Acquir Immune Defic Syndr. 2016;72(5):485\u201391.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2680_CR68","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","volume":"59","author":"M Feng","year":"2015","unstructured":"Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59(1):590\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2680_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/QAI.0b013e31823aca74","volume":"59","author":"R Kulkarni","year":"2012","unstructured":"Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59(1):47\u201354.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2680_CR70","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.jmedchem.2c01574","volume":"66","author":"L Prener","year":"2023","unstructured":"Prener L, Baszczynski O, Kaiser MM, Dracinsky M, Stepan G, Lee YJ, Brumshtein B, Yu H, Jansa P, Lansdon EB, et al. Design and synthesis of novel HIV-1 NNRTIs with bicyclic cores and with improved physicochemical properties. J Med Chem. 2023;66(3):1761\u201377.","journal-title":"J Med Chem"},{"key":"2680_CR71","unstructured":"Pages LBPJC, Menendez RF, Velando EPF, Del Valle SG, Diaz MLL, Losana AM, Wolfendale MJ. Glaxo Group: (pyrazol-3-yl) -1, 3, 4-thiadiazol-2-amine and (pyrazol-3-yl)-1, 3, 4-thiazol-2-amine compounds. In: US; 2010."},{"issue":"10","key":"2680_CR72","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1021\/jm1002233","volume":"53","author":"EB Lansdon","year":"2010","unstructured":"Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem. 2010;53(10):4295\u20139.","journal-title":"J Med Chem"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02680-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:25:44Z","timestamp":1741368344000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02680-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02680-3","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}